Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 06:30:00 12/03/2026 GMT			5-day change	1st Jan Change
2,900.00 ^JPY	+1.59%		+1.97%	-13.38%

03-09	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
03-09	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT

Transcript : Daiichi Sankyo Company, Limited, Q3 2026 Earnings Call, Jan 30, 2026

Published on 01/30/2026 at 08:35 am GMT - Modified on 01/30/2026 at 09:38 am GMT

S&P Capital IQ

Presenter Speech
Kentaro Asakura (Executives)

Ladies and gentlemen, thank you very much for your patience. Now we would like to start FY 2025 Third Quarter Financial Results Presentation. I am from

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Daiichi Sankyo Company, Limited

03-09	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
03-09	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT
03-09	Astra drug wins US review as oil surges above USD100	AN
03-09	AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer	MT
03-09	Daiichi Sankyo says Enhertu gets U.S. Priority Review for HER2-positive early breast cancer	RE
03-09	AstraZeneca and Daiichi secure US fast-track status for cancer drug	AN
03-09	AstraZeneca, Daiichi Sankyo's Enhertu Receives US FDA Priority Review Status in Early Breast Cancer	MT
03-09	Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer	CI
02-26	Daiichi Sankyo Submits Supplemental New Drug Application for Enhertu as Adjuvant Therapy for Her2 Positive Early Breast Cancer in Japan	CI
02-26	Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026	CI
02-25	Daiichi Sankyo Company, Limited Announces Retirement of Sunao Manabe as Representative Director Executive Chairperson, Effective February 26, 2026	CI
02-24	Avacta hails new data supporting proprietary preCision platform	AN
02-24	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT
02-24	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
02-23	Daiichi Sankyo Company, Limited Announces Executive Changes Effective from April 1, 2026	CI